Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 4 1Phase 3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Endometriosis 1Colonic Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × Atorvastatin × Clear all
NCT03560882 2026-05-06

A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

University of Kansas Medical Center

Phase 1 Active not recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡